<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723252</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2018-127</org_study_id>
    <nct_id>NCT03723252</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Efficacy and Action in NASH</brief_title>
  <acronym>DEAN</acronym>
  <official_title>Efficacy and Safety of Dapagliflozin in Non-alcoholic Steatohepatitis: a Multicentre, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety
      of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies
      and metabolic risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in scored liver histological improvement over 12 months</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of NASH</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fibrosis score</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in each component score in the NAS</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver fat</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipids</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory markers of NASH</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life scores (SF-12)</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dapagliflozin 10mg po qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo po qd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Participants will receive dapagliflozin 10mg po qd</description>
    <arm_group_label>Dapagliflozin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo po qd</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged≥18 years;

          -  Non-alcoholic steatohepatitis as determined by liver biopsies within 6 months;

          -  Patients with T2DM at screening had to have stable glycaemic control (HbA1c &lt;9.5%) .

        Exclusion Criteria:

          1. Significant alcohol consumption in the past six months (Consumed more than 20 g/day
             for women or 30 g/day for men);

          2. A history of alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis,
             autoimmune hepatitis, cirrhosis, and liver cancer;

          3. Obstructive biliary disease;

          4. Having any medical condition that would affect metabolism (i.e. Cushing syndrome,
             known hyperthyroidism or hypothyroidism);

          5. Poor glucose control (defined as HbA1C≤ 9.5% within 3 months) if diagnosed with T2DM,
             or taking any antidiabetic medication that would affect metabolism or weight loss
             (i.e. TZD, GLP-1, DPP-4i or initially using insulin in the past 3 months);

          6. Taking any medication (i.e. cortisol, methotrexate)that would affect steatohepatitis
             for more than two weeks in the past year;

          7. Chronic kidney disease or severe impaired renal function (serum creatinine≥ 2.0mg/dl);

          8. Serum alanine aminotransferase (ALT) greater than 300U/L

          9. A history of Type 1 diabetes;

         10. A history of bladder cancer;

         11. Women who are pregnant or plan to become pregnant;

         12. Serious medical disease with likely life expectancy less than 5 years;

         13. Patients who cannot be followed for 24 months (due to a health situation or
             migration);

         14. Participation in other clinical trial in the 30 days before randomization;

         15. Patients who are unwilling or unable to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huijie Zhang, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huijie Zhang, MD.PhD.</last_name>
    <phone>+86-020-61641635</phone>
    <email>Huijiezhang2005@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinjun Chen, MD.PhD.</last_name>
    <phone>+86-020-62787310</phone>
    <email>chjj@smu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huijie Zhang, MD,PhD</last_name>
      <phone>+86-020-61641635</phone>
      <email>Huijiezhang2005@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Huijie Zhang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>SGLT-2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

